Crossmark Global Holdings Inc. Invests $866,000 in Immunocore Holdings plc (NASDAQ:IMCR)

Crossmark Global Holdings Inc. bought a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 27,803 shares of the company’s stock, valued at approximately $866,000. Crossmark Global Holdings Inc. owned 0.06% of Immunocore at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in IMCR. Exchange Traded Concepts LLC boosted its holdings in shares of Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares in the last quarter. Tidal Investments LLC acquired a new stake in Immunocore in the first quarter worth $423,000. Nan Fung Group Holdings Ltd bought a new stake in Immunocore in the first quarter valued at $439,000. Connective Portfolio Management LLC acquired a new position in shares of Immunocore during the third quarter valued at about $218,000. Finally, DNB Asset Management AS boosted its position in shares of Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IMCR has been the subject of a number of research analyst reports. UBS Group assumed coverage on Immunocore in a research report on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Needham & Company LLC lowered their price objective on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Guggenheim cut shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $69.18.

Immunocore Trading Down 4.5 %

NASDAQ:IMCR opened at $32.62 on Friday. Immunocore Holdings plc has a 52 week low of $29.72 and a 52 week high of $76.98. The firm has a 50-day moving average price of $32.52 and a two-hundred day moving average price of $38.89. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -34.34 and a beta of 0.72.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same period last year, the company posted ($0.59) earnings per share. Immunocore’s quarterly revenue was up 23.7% compared to the same quarter last year. On average, equities analysts expect that Immunocore Holdings plc will post -0.96 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.